Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087

Peringkat dalam Saham #3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Harga Saham
$10.03
Kapitalisasi Pasar
$5.99B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
2.30%
Negara
CN
Perdagangan Gan & Lee Pharmaceuticals. (603087)

Kategori

Healthcare
Riwayat dividen untuk Gan & Lee Pharmaceuticals. (603087)
Saham Gan & Lee Pharmaceuticals. (simbol: 603087) telah membayar total 7 dividen.
Total semua dividen (disesuaikan dengan stock split): $3.76
Imbal hasil dividen (TTM): 0.0149
Pembayaran dividen untuk Gan & Lee Pharmaceuticals. (603087) dari 2020 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
2026 (TTM) $1.00 0.00%
2025 $1.00 42.86%
2024 $0.7 133.33%
2022 $0.3 -25.00%
2021 $0.4 12.01%
2020 $0.3571 0.00%
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
2026 (TTM) $1.00 0.00%
2025 $1.00 42.86%
2024 $0.7 133.33%
2022 $0.3 -25.00%
2021 $0.4 12.01%
2020 $0.3571 0.00%
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
0.00%
US
27.00%
FR
0.00%
JP
175.00%
US
0.00%
CH